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ABSTRACT
Background. Data from patients with colorectal liver
metastases (CRLM) who received neoadjuvant chemo-
therapy before resection were reviewed and evaluated to
see whether neoadjuvant chemotherapy inﬂuences the
predictive outcome of R1 resections (margin is 0 mm) in
patients with CRLM.
Methods. Between January 2000 and December 2008, all
consecutive patients undergoing liver resection for CRLM
were analyzed. Patients were divided into those who did
and did not receive neoadjuvant chemotherapy. The out-
come after R0 (tumor-free margin[0 mm) and R1 (tumor-
free margin 0 mm) resection was compared.
Results. A total of 264 were eligible for analysis. Median
follow-up was 34 months. Patients without chemotherapy
showed a signiﬁcant difference in median disease-free
survival (DFS) after R0 or R1 resection: 17 [95% conﬁ-
dence interval (CI) 10–24] months versus 8 (95% CI 4–12)
months (P\0.001), whereas in patients with neoadjuvant
chemotherapy the difference in DFS between R0 and R1
resection was not signiﬁcant: 18 (95% CI 10–26) months
versus 9 (95% CI 0–20) months (P = 0.303). Patients
without chemotherapy showed a signiﬁcant difference in
median overall survival (OS) after R0 or R1 resection: 53
(95% CI 40–66) months versus 30 (95% CI 13–47) months
(P\0.001). In patients with neoadjuvant chemotherapy,
the median OS showed no signiﬁcant difference: 65 (95%
CI 39–92) months for the R0 group versus the R1 group, in
whom the median OS was not reached (P = 0.645).
Conclusions. In patients treated with neoadjuvant che-
motherapy, R1 resection was of no predictive value for
DFS and OS.
Without treatment, patients with colorectal liver metas-
tases (CRLM) have a median survival of 5–8 months.
1–3
Unfortunately, only approximately 20–30% of patients with
CRLM have resectable disease at the time of diagnosis.
4,5
After resection, 5-year survival rates of 21–48% have been
reported.
6–8 Nowadays, chemotherapy regimens are highly
effective and can result in response rates of 50–80% and
seem to convert 10–30% of formerly irresectable CRLM to
a resectable size or situation.
6,7,9,10
Several studies have described risk factors for the out-
come of patients with CRLM.
8,11–17 Surgical margin status
has been described as the major determinant of survival
after resection, with R1 resections doing worse compared
to R0 resections. However, the impact of the several pro-
posed cutoff points regarding R0 resections remains
controversial.
Some older studies proposed a surgical margin of
B1 cm as a contraindication for resection.
16,18–20 Others
demonstrated that a resection margin B1 cm is not a con-
traindication, providing a radical resection (minimal
margin of 1 mm) is performed.
21–25
However, these studies did not evaluate the speciﬁc
group of patients who received neoadjuvant chemotherapy
before resection of CRLM. Therefore, the present study
analyzes whether a resection margin of 0 mm is sufﬁcient
in the era of effective neoadjuvant chemotherapy.
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description of surgical margin status by the pathologist for
each metastasis; no evidence of concomitant extrahepatic
disease; no simultaneous use of local treatment modalities
(radiofrequency ablation and/or cryotherapy).
26
All patients underwent preoperative screening to assess
theextentofthemetastasesbyclinicalexaminationandchest
and abdominal imaging (ultrasound, computed tomography
[CT],magneticresonanceimaging).Inourinstitute,positron
emission tomography is not routinely used. Also, serum
tumor marker levels (carcinoembryonic antigen, CEA) and
colonoscopy were performed preoperatively.
Chemotherapy
We are a tertiary referral hospital, and we do not
administer perioperative chemotherapy as a standard
treatment protocol for patients with CRLM. Most patients
had already received neoadjuvant chemotherapy in the
referring hospital. In our clinic, patients received neoad-
juvant chemotherapy in cases of initially difﬁcult/
unresectable liver metastases (poor location) or multiple
synchronous metastases C4. Patients received a combina-
tion of 5-ﬂuorouracil/capecitabine and oxaliplatin or
irinotecan, with or without bevacizumab. The response to
neoadjuvant chemotherapy was assessed after two or three
cycles by CT scan and CEA levels. Further treatment was
discussed according to the tumor response and extent of the
disease. When the liver metastases were resectable, a lap-
arotomy was planned more than 3 weeks after the last
course of systemic neoadjuvant chemotherapy. Bev-
acizumab had to be excluded from the last course of
chemotherapy to ensure an interval of at least 6 weeks.
None of the patients received adjuvant chemotherapy as
standard therapy after liver resection. The time period from
2000 was chosen because of the introduction of more
effective chemotherapy and also because after 2000 the
deﬁnition of resectability was not changed in our clinic.
Liver Resection
Hepatic parenchymal resection was performed with an
ultrasonic surgical aspirator (Cavitron; Valleylab, Boulder,
CO) and a monopolar coagulator. R0 was deﬁned by the
absence of microscopic tumor invasion of the resection
margin (tumor-free margin [0 mm), and R1 was deﬁned
by the presence or microscopic tumor invasion of the
resection margin (tumor-free margin 0 mm).
Follow-up
Postoperativefollow-up consisted of clinical examination
and measurement of CEA every 3 months. Abdominal
imaging (ultrasound, CT of thorax and abdomen) was per-
formed at 3, 6, 9, and 12 months in the ﬁrst year; every
6 months the second year; and once a year thereafter. If dis-
easerecurred,adecisiononwhethertoinitiatechemotherapy
treatment again was made by the multidisciplinary team.
Outcome
Overall survival (OS) was deﬁned as the interval in
months between resection of CRLM and death, or the date
of last follow-up. Disease-free survival (DFS) was deﬁned
as the interval in months between resection of CRLM and
recurrence, death without recurrence, or date of last follow-
up without recurrence.
Statistical Analysis
Descriptive values are expressed as median (range).
Comparison between categorical variables was determined
by the chi-square test or Fisher’s exact test as appropriate.
Survival analysis was performed by the Kaplan–Meier
method. Comparison between survival curves was made by
log rank tests. Univariate analysis was performed by Cox
regression analysis. For the multivariate analysis, only
parameters with a P value of\0.25 in the univariate model
were entered in the Cox regression model. Backward
elimination was applied. Variables were included if P val-
ues were B0.05 and were removed if P values were[0.10.
SPSS statistical software, version 17.0 (SPSS, Chicago,
IL), was used for statistical analysis; a P value of B0.05
was considered statistically signiﬁcant.
RESULTS
Between January 2000 and December 2008, a total of
352 patients underwent liver resection for CRLM (Fig. 1).
Of these, 81 patients (23%) were excluded because of
extrahepatic disease, concomitant local treatment, and/or
macroscopic incomplete liver resection. Seven patients
(2%) had unknown margin status. Finally, 264 patients
(75%) were eligible for analysis. One patient was lost to
follow-up at 21 months. Neoadjuvant chemotherapy was
provided to 92 (35%) of 264 patients. Thirty-eight patients
(41%) received concomitant bevacizumab.
Patient characteristics are listed in Tables 1 and 2.A n
R1 resection was found in 33 patients (13%). R1 resections
in patients without chemotherapy and with chemotherapy
were comparable: 13 vs. 12% (P = 0.845).
R0 vs. R1 Resection in Patients with Neoadjuvant Chemotherapy 1619The median follow-up was 34 (range 0–121) months.
Five patients (1.9%) died postoperatively, 3 due to liver
and kidney failure and 2 due to aspiration followed by
sepsis.
The median DFS was 14 [95% conﬁdence interval (CI)
10–18] months for patients without chemotherapy, and for
patients with neoadjuvant chemotherapy it was 16 (95% CI
8–24) months (P = 0.962). In patients without chemo-
therapy, the median DFS showed a signiﬁcant difference
between the R0 and R1 resection: 17 (95% CI 10–24)
months versus 8 (95% CI 4–12) months (P\0.001). In
patients with neoadjuvant chemotherapy, the median DFS
showed no signiﬁcant difference between the R0 and R1
resection: 18 (95% CI 10–26) months versus 9 (95% CI
0–20) months (P = 0.303) (Fig. 2).
During follow-up, 171 patients (65%) developed recur-
rence. Local treatment was performed in 74 patients (43%)
(surgery, radiofrequency ablation, stereotactic radiother-
apy), 80 patients (47%) received palliative chemotherapy,
and 17 patients (10%) did not receive chemotherapy or
local treatment. There was no difference in treatment of the
recurrence between patients who were treated with or
without neoadjuvant chemotherapy (P = 0.253). FIG. 1 Flowchart of the study
TABLE 1 Characteristics of
patients by chemotherapy
treatment






P value All patients
(n = 264)
Value Value Value
Male sex 107 (62%) 62 (67%) 0.403 169 (64%)
Age 65 (30–86) 62 (36–84) 0.714 64 (30–86)
Primary tumor
Rectal cancer 84 (49%) 45 (49%) 0.991 129 (49%)
T stage
T3 124 (72%) 66 (72%) 190 (72%)
T4 12 (7%) 8 (9%) 20 (8%)
Missing data – 2 (2%) 2 (1%)
Positive lymph node 97 (56%) 56 (61%) 0.364 153 (58%)
Missing data – 2 (2%) 2 (1%)
Liver metastases
Synchronous 52 (30%) 67 (73%) \0.001 119 (45%)
Diameter (cm)
Median (range) 3.3 (0.9–15) 3.5 (0.5–18) 0.068 3.4 (0.5–18)
Missing data 2 (1%) 2 (2%) 4 (2%)
No. of metastases \0.001
Median (range) 1 (1–8) 2.0 (1–8) 2 (1–8)
Missing data 1 (1%) – 1 (0.5%)
Bilobar 43 (25%) 36 (39%) 0.017 79 (30%)
Resection type 0.544
Anatomical 78 (45%) 41 (45%) 119 (45%)
Nonanatomical 69 (40%) 33 (36%) 102 (39%)
Combined 25 (15%) 18 (20%) 43 (16%)
R1 resection 22 (13%) 11 (12%) 0.845 33 (13%)
1620 N. Ayez et al.In total, 54 patients (20%) had intrahepatic recurrence
only, 87 patients (33%) had extrahepatic recurrence only,
and 30 patients (11%) had intrahepatic and extrahepatic
recurrence. There was no difference in recurrences located
at the surgical liver margins between R0 and R1 resection
in patients with and without chemotherapy (P = 0.853 and
P = 0.839, respectively).
The median OS was 48 (95% CI 39–57) months for
patients without chemotherapy and 65 months (95% CI not
reached) for patients with neoadjuvant chemotherapy
(P = 0.103). In patients without chemotherapy, the median
OS showed a signiﬁcant difference between R0 and R1
resection: 53 (95% CI 40–66) months versus 30 (95% CI
13–47) months (P\0.001). In patients with neoadjuvant
chemotherapy, the median OS showed no signiﬁcant dif-
ference between the R0 resection, 65 (95% CI 39–92)
months, and the R1 resection, where the median OS was
not reached (P = 0.645) (Fig. 2).
A similar trend was found if a tumor-free margins of
0–2 mm versus [2 mm and 0–5 mm versus [5 mm was
chosen. The 5-year OS was 35% for patients without
neoadjuvant chemotherapy who had R0 resection with
B2 mm from the resection margin (n = 42), whereas for
patients who had a R0 resection with [2 mm from the
resection margin (n = 100), the 5-year OS was 51%
(P = 0.04). In patients with neoadjuvant chemotherapy,
this phenomenon could not be demonstrated: 65% (n = 28)
versus 45% (n = 48) (P = 0.564). When comparing 0–5
mm versus [5 mm, the 5-year OS was 55 vs. 36% in
patients without chemotherapy (P = 0.062) and 44 vs.
63% in patients with chemotherapy (P = 0.361).
Predictive factors in univariate and multivariate analysis
are listed in Table 3. In the total study population of 264
patients, multivariate analysis showed four factors predic-
tive for survival: T stage primary tumor [hazard ratio
(HR) = 2.0 [95% CI 1.1–3.5]; P = 0.016]. Positive lymph
nodes in primary tumor (HR = 1.5 [95% CI 1.0–2.2];
P = 0.039), number of metastases (C4) (HR = 1.8 [95%
CI 1.1–2.9]; P = 0.028) and neoadjuvant chemotherapy
(HR = 0.62 [95% CI 0.4–0.9]; P = 0.027).
DISCUSSION
This study reviews patients with CRLM who received
neoadjuvant chemotherapy before resection and evaluates
TABLE 2 Characteristics of
patients by resection margin
Data are presented as n (%)
unless otherwise indicated
Characteristic R0 (n = 231) R1 (n = 33) P value All patients
(n = 264)
Male 152 (66%) 17 (52%) 0.123 169 (64%)
Age, median (range) 64 (31–86) 62 (30–77) 0.499 64 (30–86)
Primary tumor
Rectal cancer 117 (51%) 12 (36%) 0.139 129 (49%)
T stage 0.682
T3 163 (71%) 27 (82%) 190 (72%)
T4 18 (8%) 2 (6%) 20 (8%)
Missing data 2 (1%) – 2 (1%)
Positive lymph node 127 (55%) 26 (79%) 0.011 153 (58%)
Missing data 2 (1%) 2 (1%)
Liver metastases
Synchronous 106 (46%) 13 (39%) 0.483 119 (45%)
Diameter (cm) 0.048
Median (range) 3.2 (0.5–18) 3.9 (1.6–7.0) 3.4 (0.5–18)
Missing data 4 (2%) – 4 (2%)
No. metastases 0.173
Median 1 (1–8) 3.0 (1–8) 2 (1–8)
Missing data 1 (1%) – 1 (0.5%)
Bilobar 61 (26%) 18 (55%) 0.001 79 (30%)
Resection type 0.513
Anatomical 107 (46%) 12 (37%) 119 (45%)
Nonanatomical 88 (38%) 14 (42%) 102 (39%)
Combined 36 (16%) 7 (21%) 43 (16%)
Chemotherapy
Neoadjuvant chemotherapy 81 (35%) 11 (33%) 0.845 92 (35%)
R0 vs. R1 Resection in Patients with Neoadjuvant Chemotherapy 1621whether neoadjuvant chemotherapy affects the predictive
value of resection margins. In patients with neoadjuvant
chemotherapy, those with a R1 resection did not fare worse
than those with a R0 resection (P = 0.303 and P = 0.645,
respectively). In our series, we found 13% R1 resections,
which is comparable to data in found at other centers
(5–46%).
11,18,21,26–29
Earlier studies found that a clear resection margin of
1 cm was found to be a good predictor of survival.
30,31
Others have conﬁrmed these results.
16,18–20 With new
insights in CRLM surgery in the last decade, some report
that the 1-cm rule is outdated and should not preclude
resection, provided a complete resection is possible.
21–25,32
De Haas et al. even reported that they did not ﬁnd any
difference in DFS and OS between R0 and R1 resections
(P = 0.12 and P = 0.27, respectively).
26 In their study,
74% of the patients received neoadjuvant chemotherapy
and 26% did not receive neoadjuvant chemotherapy;
however, they did not describe these two groups separately.
In 83% of their patients, surgery was followed by adjuvant
chemotherapy.
The present study demonstrates comparable results
when we divide the cohort into patients who did and did
not receive neoadjuvant chemotherapy. However, one
major difference is that none of our patients received
adjuvant chemotherapy after CRLM surgery. As yet, to our
knowledge, there are no randomized data to support adju-
vant chemotherapy alone after liver resection. The liver
FIG. 2 R0 versus R1 resection
in patients without and with
chemotherapy for DFS and OS
1622 N. Ayez et al.TABLE 3 Data on univariate and multivariate analysis















Male 14 (10–18) 0.95 (0.65–1.39), 0.789 NS 17 (6–28) 1.03 (0.60–1.77), 0.914 NS
Female 13 (7–19) 14 (3–25)
Age
\60 years 14 (4–24) 1.09 (0.72–1.64), 0.692 NS 11 (6–16) 0.87 (0.52–1.48), 0.617 NS
C60 years 14 (10–18) 21 (13–29)
Primary tumor
Rectum 13 (10–16) 0.86 (0.60–1.25), 0.440 NS 17 (3–31) 1.23 (0.73–2.08), 0.440 NS
Colon 15 (9–21) 15 (4–26)
T stage primary tumor
T1–3 15 (11–19) 2.00 (1.07–3.73), 0.029 2.52 (1.33–4.76) 18 (11–25) 2.56 (1.16–5.67), 0.021 2.4 (1.08–5.34)
T4 6 (0–14) 0.004 4 (1–7) 0.032
Lymph node
Negative 26 (0–57) 1.70 (1.4–2.5), 0.009 1.53 (1.02–2.29) 16 (0–36) 1.29 (0.74–2.24), 0.371 2.35 (1.28–4.31)
Positive 10 (6–14) 0.042 17 (8–26) 0.006
Hepatic metastases
Time diagnosis
Metachronous 15 (8–22) 1.30 (0.9–1.9), 0.174 NS 19 (8–30) 1.10 (0.61–1.98), 0.751 NS
Synchronous 13 (8–18) 14 (7–21)
No. of metastases
B3 26 (0–57) 2.00 (1.1–3.5), 0.024 NS 21 (9–33) 2.47 (1.37–4.44), 0.003 NS
C4 10 (6–14) 6 (5–7)
Largest metastasis size
\4 16 (10–22) 1.10 (0.75–1.62), 0.637 NS 12 (6–18) 0.74 (0.40–1.37), 0.338 NS
C4 11 (8–140 23 (0–64)
Tumor distribution
Unilobar 16 (8–24) 1.41 (0.94–2.10), 0.093 NS 21 (0–44) 1.80 (1.07–3.03), 0.027 NS
Bilobar 10 (8–12) 11 (7–15)
CEA level
\50 16 (11–21) 1.39 (0.91–2.11), 0.129 NS 15 (7–23) 1.06 (0.48–2.35), 0.880 NS
C50 8 (4–12) 21 (0–50)
Resection margin
R0 17 (10–24) 3.08 (1.90–5.01),\0.001 2.86 (1.70–4.78) 18 (10–26) 1.44 (0.71–2.94), 0.315 NS
R1 8 (4–12) \0.001 9 (0–20)
Overall survival
Sex
Male 46 (38–54) 0.84 (0.55–1.30), 0.434 NS 65 (NR) 0.98 (0.47–2.03), 0.951 NS
Female 54 (27–81) NR
Age
\60 years 53 (41–65) 1.13 (0.72–1.77), 0.600 NS NR 0.81 (0.40–1.62), 0.544 NS
C60 years 43 (33–53) 65 (NR)
Primary tumor
Rectum 42 (28–56) 0.92 (0.61–1.39), 0.691 NS 65 (NR) 0.74 (0.37–1.49), 0.397 NS
Colon 51 (36–66) NR
R0 vs. R1 Resection in Patients with Neoadjuvant Chemotherapy 1623represents the predominant site of cancer relapse after
curative resection of CRLM, with up to 50% in the ﬁrst
2 years.
33,34 Thus, there is a rationale for perioperative
chemotherapy, although controversy remains. The role of
perioperative chemotherapy in the case of resectable
metastases was investigated in one randomized controlled
trial, which compared perioperative chemotherapy with
surgery alone.
35 It remains unknown whether the positive
effects reported in the treatment arm were related to neo-
adjuvant chemotherapy and/or to adjuvant chemotherapy.
A study by Adam et al. answered the pending question
whether perioperative chemotherapy is really beneﬁcial in
patients developing solitary metastases.
36 Although pre-
operative chemotherapy does not seem to beneﬁt the
outcome of patients with solitary metachronous CRLM,
postoperative chemotherapy is associated with better OS
and DFS, mainly when the tumor diameter exceeds 5 cm.
36
In four randomized trials, liver resection was followed by
adjuvant systemic chemotherapy or observation.
37–40 None
of the studies displayed an OS or DFS beneﬁt. Mitry et al.
performed a meta-analysis from two trials above.
41 In
multivariate analysis, adjuvant chemotherapy was inde-
pendently associated with progression-free survival.
Although there are strong theoretical arguments in favor of
adjuvant systemic chemotherapy after resection of liver
metastases, the evidence to suggest an improvement in
survival after this regime is still lacking.
42
Hou et al. found no difference in OS between R0 and
R1 resections in patients with colorectal metastases
(P = 0.0776). In their study, patients did not receive
neoadjuvant chemotherapy but were administered adju-
vant hepatic arterial chemotherapy after resection.
Furthermore, they used additional cryotherapy after
resection of CRLM.
43 Yan et al. also suggested that
cryotherapy is useful after resection of CRLM; they
found no difference between close or involved surgical
margins (P = 0.084).
44 It is possible that in case of
additional cryotherapy, the micrometastases that were
TABLE 3 continued










(95% CI), P value
Multivariate
HR (95% CI)
T stage primary tumor
T1–3 51 (40–62) 1.72 (0.86–3.43), 0.122 NS NR 2.84 (1.08–7.49), 0.035 2.84 (1.08–7.59)
T4 34 (3–65) 32 (16–48) 0.035
Lymph node
Negative 64 (44–84) 1.45 (0.95–2.22), 0.084 NS 65 (31–99) 1.53 (0.70–3.34), 0.287 NS
Positive 42 (28–56) NR
Hepatic metastases
Time diagnosis
Metachronous 54 (41–67) 1.18 (0.77–1.82), 0.443 NS 46 (NR) 0.93 (0.43–2.01), 0.851 NS
Synchronous 42 (38–46) NR
No. of metastases
B3 48 (37–59) 1.68 (0.87–3.26), 0.123 NS NR 2.24 (1.06–4.75), 0.036 NS
C4 32 (14–50) 43 (27–59)
Largest metastasis size
\4 46 (37–55) 1.05 (0.69–1.62), 0.811 NS 65 (35–95) 0.55 (0.21–1.43), 0.220 NS
C4 48 (27–69) NR
Tumor distribution
Unilobar 51 (39–63) 1.11 (0.71–1.74), 0.639 NS NR 2.13 (1.06–4.29), 0.035 NS
Bilobar 42 (29–55) 45 (NR)
CEA level
\50 51 (41–61) 1.37 (0.85–2.10), 0.208 NS 65 (NR) 0.49 (0.12–2.07), 0.335 NS
C50 36 (16–56) NR
Resection margin
R0 53 (40–66) 2.42 (1.45–4.03), 0.001 2.58 (1.54–4.33) 65 (NR) 0.78 (0.27–2.24), 0.647 NS
R1 30 (13–47) \0.001 NR
NS not signiﬁcant, NR not reached
1624 N. Ayez et al.not resected were eliminated by the edge cryotherapy
because edge cryotherapy can provide an area of tumor
eradication of up to another 1 cm.
To explain these results, it is necessary to consider
several characteristics of CRLM. One feature is microm-
etastases.
45–47 Some found that approximately 95% of
intrahepatic micrometastases are found in the close zone
of\1 cm from the gross hepatic tumor, and therefore
suggested that a resection margin of 1 cm should remain
the goal for resection of CRLM.
47 Others collected positive
samples only within 4 mm of the tumor border.
46,48 Nanko
et al. state that the bigger the macrometastases, the more
micrometastases, and the further away they are located.
45
Yamamoto et al. could not demonstrate a relationship
between distance and tumor size.
49 Because there are
several methods for detection of micrometastases, not all
investigators report similar results on incidence. For
example, when genetic analysis is used, only 2% of mi-
crometastases were detected, whereas with basic
histopathology, a detection rate of 56% was achieved, and
with immunohistochemical staining, the detection rate is
58%.
45–47 These differences in detection method might
explain why micrometastases distribution is very different
in these studies.
It is widely accepted that neoadjuvant chemotherapy can
decrease the size of metastases. But how neoadjuvant
chemotherapy decreases the size of CRLM remains
unclear. Ng et al. showed that cell death is randomly
distributed, probably as a result of variations in chemo-
sensitivity of tumor cells, and that tumor shrinkage occurs
in a concentric manner.
48 They also found that viable
tumor cells were more frequent in the periphery of
metastases, whether or not they were treated with chemo-
therapy. Mentha et al. reported similar results with the
ﬁnding of a dangerous ‘‘halo’’ (regrowth occurring at the
periphery rather than in the center of the metastasis when
chemotherapy is interrupted).
50 They state that the surgeon
should aim for a wider resection margin than 1 mm.
Nevertheless, Klinger et al. rarely observed a dangerous
halo.
51 In their study, the tumor glands were located mostly
in the periphery of the metastases but were still covered by
a layer of ﬁbrotic tissue, and therefore parenchymal tran-
section could be performed within the new borders (after
response to chemotherapy) without increasing the inci-
dence of local recurrence.
51 This phenomenon supports our
results.
Neoadjuvant chemotherapy is able to shrink the tumor,
as described before. We believe that this is a concentric
rather than a scattering response, as sometimes seen in
primary tumors; perhaps micrometastases in the periphery
of the tumor were destroyed.
52 This could explain
why recurrence was similar in R0 and R1 resection in
patients who received neoadjuvant chemotherapy. This
also explains the successful downsizing of formerly unre-
sectable metastases into resectable metastases with almost
the same outcome in primary resectable cases. A concern
of neoadjuvant chemotherapy might be the disappearance
of smaller lesions after several lines of chemotherapy and
the difﬁculty identifying these lesions during surgery. The
need to resect all tumors observed on the prechemotherapy
imaging was demonstrated previously.
53,54 Another con-
cern of chemotherapy is additional complications after
liver resection. However, it is known from the literature
that if limited cycles of chemotherapy are provided in the
neoadjuvant setting, the morbidity or mortality of liver
surgery is not increased.
55,56 Therefore, we administer to
our patients\6 cycles of chemotherapy and evaluate after
2–3 cycles.
Several authors state that the width of the nega-
tive margins (R0) does not show a correlation with
survival.
21,22,25,57 In all these studies, a considerable pro-
portion of the patients received neoadjuvant chemotherapy
and/or adjuvant chemotherapy. In our study, we demon-
strated in both univariate and multivariate analyses that the
5-year OS for patients without neoadjuvant chemotherapy
showed a marked difference between R0 and R1 resection.
Others proposed that margin widths of 2 and 5 mm,
respectively, were acceptable and led to similar outcomes
compared with 1-cm margin resection.
28,29,46 We also
analyzed whether margin width B2m mo r[2 mm inﬂu-
enced survival. This proved to be the case (P = 0.04) in
patients who had a R0 resection without neoadjuvant
chemotherapy. In patients with neoadjuvant chemotherapy,
this phenomenon could not be demonstrated (P = 0.564).
A similar trend was found if a tumor-free margins of
0–5 mm versus[5 mm was chosen. It seems that the width
of the resection margin still correlates with survival, but
this only applies to patients who did not receive chemo-
therapy. This supports our hypothesis that neoadjuvant
chemotherapy is able to destroy micrometastases in the
periphery, and that in patients, the same survival rate,
regardless of the width of the negative margins, is
achieved. Therefore, data should be revised, and patients
who did and did not receive chemotherapy should be
investigated separately.
Yamamoto et al. described another feature of some
CRLM.
49 They found that one third of their patients have a
thick ﬁbrous pseudocapsule and suggested that a generous
surgical margin is not required for resection. Later, the
same group reported on a larger cohort and demonstrated
that a thicker pseudocapsule leads to fewer R1/R2 resec-
tions.
58 Although not signiﬁcant, there was some relation
between the presence of a pseudocapsule and the ability to
achieve complete resection. Pseudocapsule formation was
not available in our data set, so we could not compare this
in the different chemotherapy groups.
R0 vs. R1 Resection in Patients with Neoadjuvant Chemotherapy 1625In conclusion, in the present series, the DFS and OS in
patients with neoadjuvant chemotherapy is similar for
patients with either R0 or R1 resection.
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